-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, 2022, Novartis announced that 177Lu-PSMA-617 was approved by the FDA for the treatment of PSMA-positive, treatment-progressed castration-resistant prostate cancer under the trade name Pluvicto
.
The FDA also approved gallium-68 as a contrast agent for PSMA-positive tumors under the trade name Locametz
.
The radiation dose of Pluvicto was measured at 1000 MBq/ml, and the half-life of Lutetium 177 was 6.
647 days
.
As a nuclear drug, Pluvicto combines targeting ligands and radioisotope therapy, targeting PSMA-positive cells, and causing DNA damage through radioisotopes to kill tumor cells
.
The approval of Pluvicto is based on the data of the Phase III clinical VISION, the overall response rate of the treatment is 30%, of which the complete response rate is 6%, and the treatment reduces the risk of death by 38%
.
The safety figures for Pluvicto are as follows
.
Novartis is expanding the range of treatments for Pluvicto
.
Conclusion The approval of Pluvicto marks another major progress in the field of nuclear medicine, and provides an important treatment for many refractory cancers
.
Novartis also has a number of nuclear drugs under development, most of which use the lutetium-177 isotope
.
Disclaimer The article reproduced by "Yaodu" comes from the public account: Medical Notes.
The main purpose is to share industry-related knowledge and deliver the latest information
.
The copyrights of pictures and articles belong to the original authors.
If there is any infringement, please inform us in time, and we will delete the relevant information within 24 hours
.
.
The FDA also approved gallium-68 as a contrast agent for PSMA-positive tumors under the trade name Locametz
.
The radiation dose of Pluvicto was measured at 1000 MBq/ml, and the half-life of Lutetium 177 was 6.
647 days
.
As a nuclear drug, Pluvicto combines targeting ligands and radioisotope therapy, targeting PSMA-positive cells, and causing DNA damage through radioisotopes to kill tumor cells
.
The approval of Pluvicto is based on the data of the Phase III clinical VISION, the overall response rate of the treatment is 30%, of which the complete response rate is 6%, and the treatment reduces the risk of death by 38%
.
The safety figures for Pluvicto are as follows
.
Novartis is expanding the range of treatments for Pluvicto
.
Conclusion The approval of Pluvicto marks another major progress in the field of nuclear medicine, and provides an important treatment for many refractory cancers
.
Novartis also has a number of nuclear drugs under development, most of which use the lutetium-177 isotope
.
Disclaimer The article reproduced by "Yaodu" comes from the public account: Medical Notes.
The main purpose is to share industry-related knowledge and deliver the latest information
.
The copyrights of pictures and articles belong to the original authors.
If there is any infringement, please inform us in time, and we will delete the relevant information within 24 hours
.
